

Gastric Schwannoma

Tanawat Pattarapuntakul, M.D.

Nanthana-Kriangkrai Chotiwattanaphan Institute of Gastroenterology and Hepatology, Faculty of Medicine,
Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand.

Received 30 August 2017 • Accepted 26 January 2018 • Published online 24 May 2018

Abstract:

A gastric schwannoma is a rare primary spindle cell mesenchymal tumor of the digestive tract. Gastric schwannomas originate from Schwann cells of the peripheral nerves in the stomach. The majority of schwannomas are benign, slow growing tumors only a few of which develop into malignancies. Due to their indolent course, in most cases, gastric schwannomas are asymptomatic or discovered as an incidental finding on cross-sectional imaging or endoscopy. When symptomatic, the most common presenting symptoms are abdominal pain, upper gastrointestinal bleeding and intra-abdominal mass. Preoperatively, gastric schwannomas are difficult to differentiate from other mesenchymal tumors, such as gastrointestinal stroma or leiomyoma which develop from mesenchymal stem cells. The optimal management of the tumor is based on the symptoms of the patient, tumor size and histologic grading and the prognosis is excellent after complete surgical or endoscopic removal. Gastric schwannomas need multidisciplinary team management for definitive diagnosis and management, including specialists from gastroenterology, surgery, radiology and pathology.

Keywords: gastric schwannoma, gastric subepithelial tumors

Contact: Tanawat Pattarapuntakul, M.D.
Nanthana-Kriangkrai Chotiwattanaphan Institute of Gastroenterology and
Hepatology, Faculty of Medicine, Prince of Songkla University, Hat Yai,
Songkhla 90110, Thailand.
E-mail: ptanawat@medicine.psu.ac.th

JHSMR 2018;36(2):157-164
www.jhsmr.org

Introduction

A schwannoma is a rare primary spindle cell mesenchymal tumor of the digestive tract, about 73.0% of which are found in the stomach. Gastric schwannomas originate from Schwann cells of the peripheral nerves in the stomach, and represent about 2.0–7.0% of benign gastric tumors.^{1,2} The majority of schwannomas are benign, slow growing tumors, only a few of which develop into malignancies.³ There is a female predilection, with peak incidence in the 5th and 6th decades of life. The gastric schwannoma was first reported by Daimaru et al., in 1988, with confirmed diagnosis by histology and immunohistochemistry (positive S100 and glial fibrillary acidic protein).⁴ Due to their indolent course, in most cases, gastric schwannomas are asymptomatic or discovered as an incidental finding on cross-sectional imaging or endoscopy. When symptomatic, the common presenting symptoms are abdominal pain, upper gastrointestinal bleeding and intra-abdominal mass. Pre-operatively, gastric schwannomas are difficult to differentiate from other mesenchymal tumors, such as gastrointestinal stromal tumors (interstitial cells of Cajal) or leiomyoma (smooth muscle) which develop from mesenchymal stem cells.⁵ Gastric schwannomas need multidisciplinary team management for definitive diagnosis and management, including specialist from gastroenterology, surgery, radiology and pathology.

Pathogenesis

The gastric schwannoma arises from the sheath of Auerbach's plexus or, less commonly, from Meissner's plexus. The tumors are generally benign, often asymptomatic, and usually discovered incidentally from cross-sectional imaging, endoscopy, or intra-operatively. The tumor shares the characteristics of an exophytic mass extending from the gastric wall to the abdominal cavity, which have similar histology to other gastric subepithelial tumors such as gastrointestinal stromal tumors, leiomyomas and leiomyosarcomas.^{5,6} These tumors are mostly single lesion, vary in size, and are composed of spindle cell forming sheets, which have a high

blood supply but intra-tumoral slow blood flow causing overlying mucosal ischemia causing mucosal ulceration.²

Previous studies have noted a genetic association of the gastric schwannoma to monosomy variants of chromosome 22 and somatic NF2 gene mutations. These variants are more commonly associated with soft tissue schwannomas than gastric schwannomas, however these genetic variants can be found in gastric schwannomas with associated NF2 gene mutation in the presence of multiple tumor lesions and other organ involvement.^{7–11}

Prevalence and clinical manifestations

The gastric schwannoma is a primary benign mesenchymal gastric tumor, with slow growth and low malignancy potential. The incidence rate is about 0.2–1.0% of all gastric tumors and 2.0–7.0% of benign gastric mesenchymal tumors, occurring about 2–4 times more frequently in females during the 5th and 6th decades. Due to their indolent course, in most cases, gastric schwannomas are asymptomatic or discovered as an incidental finding on cross-sectional imaging or endoscopy. The common presenting symptoms are abdominal pain and upper gastrointestinal (GI) bleeding, weight loss and gastric outlet obstruction (Table 1).^{6,8} The gastric schwannoma varies in size from 1 to 10.5 cm in diameter and can be found in any part of the stomach wall that has a peripheral nerve sheath structure (Table 2).⁶

Table 1 Clinical manifestations of gastric schwannoma (n=80)^{6,8}

Clinical manifestations	Number (%)
Asymptomatic	25 (31.3)
Abdominal pain	22 (27.5)
Upper GI bleeding	10 (6.1)
Anorexia and weight loss	2 (2.5)
Gastric outlet obstruction	1 (1.3)
No data	18 (22.5)

GI=gastrointestinal

Table 2 The common locations of gastric schwannoma (n=29)⁶

Location	Number (%)
Gastric antrum	10 (34.5)
Greater curvature	7 (24.1)
Gastric fundus	6 (20.7)
Lesser curvature	5 (17.2)
Gastric cardia	1 (3.4)

Diagnosis

The gastric schwannoma is a rare primary mesenchymal tumor of the stomach which needs a multidisciplinary approach for diagnosis and management, involving specialists in gastroenterology, surgery, radiology and pathology.

Radiography

The gastric schwannoma is one of the primary gastric mesenchymal tumors, composed of spindle cells and with a high blood supply, but with an intra-tumoral slow blood flow causing overlying mucosal ischemia and subsequent mucosal ulceration. The computerized tomography findings of this tumor are shown in Table 3.¹²

A computerized tomography (CT) scan of a gastric schwannoma usually shows a single lesion with a round or oval appearance, a thin wall capsule, and exophytic growth pattern. Hemodynamically the tumor has a homogenous enhancement pattern in the arterial phase without cystic or hemorrhagic components (Figure 1). An magnetic resonance imaging (MRI) shows a low signal intensity on T1-weighted images and high signal intensity on T2-weighted images, without cystic or hemorrhagic components, and high intensity on diffusion weighted imaging.¹²⁻¹⁴ The finding of adjacent significant intra-abdominal lymph nodes, recurrent tumor or evidence of metastasis to other organs is considered to be an indication of a malignant schwannoma.

Table 3 Computerized tomography (CT) scan findings in gastric schwannoma (n=16)¹²

CT scan	Number (%)
Contour	
Round or oval	12 (75.0)
Lobulate	4 (25.0)
Margin	
Discrete	16 (100.0)
Growth pattern	
Endoluminal	1 (6.3)
Exogastric	9 (56.3)
Both	6 (37.5)
Ulceration	3 (18.8)
Cystic changes	
Present	2 (12.5)
Absent	14 (87.5)
Enhancement pattern	
Homogenous	13 (81.3)
Heterogenous	3 (18.8)

**Figure 1** A CT scan of the abdomen showing a well demarcated, round, 2*3.5*5.4 cm, heterogenous, contrast-enhanced mass with ulceration at the gastric antrum without cystic or hemorrhagic components

Endoscopy and endoscopic ultrasound

The standard upper endoscopic examination of a schwannoma shows a subepithelial mass with or without ulcerations on top of the tumor, but it should be noted that this finding is not specific to a schwannoma and can be found in other subepithelial tumors (Figure 2). An endoscopic ultrasound can improve the diagnosis of tumors in the originative layer of the tumor and intra-tumoral components, which can lead to a more accurate diagnosis of subepithelial tumors (Figure 3 and Table 4).




Figure 2 Endoscopic white-light showing a lobulated contour subepithelial mass 3*3 cm in diameter (A) with a pigmented ulcer on a mucosal tumor at the gastric antrum (B).



Figure 3 An endoscopic ultrasound showing a subepithelial heterogeneous hypoechoic mass size 2.68*1.67 cm that originated from the third layer of the stomach wall with a hypoechoic tubular structure seen in the central mass and cystic degeneration or ductal structure.

Previous studies have noted some different endoscopic ultrasound (EUS) findings which can help to distinguish schwannomas from gastrointestinal stromal tumors (GISTs). The EUS findings in a schwannoma are a heterogeneous and hypoechoic pattern which is higher than the muscularis propria and with an internal high echo area (indicating slow intratumoral blood flow) and these tumors less commonly feature cystic degeneration, hemorrhage or calcification (Table 5).¹⁶ However, although the EUS may be useful, appropriate histology is the gold standard for definitive diagnosis or EUS, with fine needle aspiration (FNA) also of benefit. Mekky et al. reported in 2010 that, EUS in combination with FNA in gastric subepithelial tumors got an appropriate tissue about 83.0% with a high rate of definite diagnosis of 96.3%.^{1,18}

Pathology

Gastric schwannomas do not have specific biochemical assay or tumor markers which allow non-invasive testing, and need histology and immunohisto-

chemistry for definitive diagnosis. The gross pathology finding of this tumor is a round thin wall capsular mass, whitish to pale or yellowish with a shiny color and whorled appearance without cystic degeneration or hemorrhage in the tumor.^{6,8}

Microscopic findings show a spindle shaped cell with nuclear palisading and no definite true capsules with microscopic ulceration present in 83.0%. Ninety-six percent of the tumors show lymphocytic cuffing at the peripheral part and about 61.0% have diffuse intratumoral lymphocyte

and plasma cell infiltrate.⁸ These findings are not sufficient, however, and immunohistochemistry is necessary for definite diagnosis. Nearly 100.0% of cases are strongly positive S100 protein, CD56 and vimentin in nearly 100.0% of cases. Glial fibrillary acidic protein is found in about 75.0% of schwannomas, including with negative CD117 (c-kit) or DOG-1 (detail in GISTs) and negative for smooth muscle actin (SMA) or desmin (detail in leiomyoma) is definite diagnosis of gastric schwannoma (Figure 4).^{6,8}

Table 4 Endoscopic ultrasound (EUS) findings in subepithelial tumors¹⁵

Tumor	EUS layer	Organ	EUS appearance
Schwannoma	4 th (3 rd)	Stomach	Hypoechoic, round or oval, well demarcated.
Gastrointestinal stromal tumors	4 th (2 nd , 3 rd)	Stomach	Hypoechoic, round or oval, well demarcated. (large tumor>4 cm, homogeneous, irregular border, cystic areas of echogenic foci)
Leiomyoma	4 th (2 nd)	Stomach	Hypoechoic, round or oval, well demarcated.
Leiomyosarcoma	4 th (2 nd)	Stomach	Hypoechoic, heterogeneous, irregular extraluminal border or invasive to adjacent organs.

Table 5 Endoscopic ultrasound findings in gastric schwannoma and low risk and high risk gastrointestinal stromal tumors (GISTs)¹⁶

Appearance	Schwannoma	Low-risk GISTs	High-risk GISTs
Echogenicity	Heterogeneous and hypoechoic, but slightly higher than MP	Homogeneous and hypoechoic	Heterogeneous and hypoechoic
Halo	Frequent	Uncertain	Uncertain
Growth	In<out (mostly)	In>out (mostly)	Variety
Margin	Regular	Regular	Irregular
Lobulation	Rare	Uncommon	Common
High echo spot	Common	Occasional	Common
Cyst	Very rare	Frequent	Very frequent
Calcification	Scarce	Occasional	Occasional




Figure 4 Microscopic and immunohistochemistry findings of gastric schwannoma

A, B, C: tumor with thin capsules with peripheral lymphoid cuff with occasional germinal center, with spindle cell and nuclear palisade appearance.

D: marked positive S100 protein (S100 is a specific marker to schwannoma)

E: negative CD117 (CD117 is a specific marker to GISTs)

F: negative SMA (SMA is a specific marker to leiomyoma)

Microscopic examination of a gastric schwannoma is necessary for evaluation of the malignancy of the tumor from nuclear atypia and mitotic count by low, moderate and high (<5, 6–10, >10 per 50 high–power field, respectively)¹⁸ and a high Ki67 expression index consider to malignant schwannoma.^{6,8}

The other common differential diagnosis items of an S100 positive tumor in the stomach are clear cell sarcoma of the stomach and metastatic malignant melanoma of the stomach.⁸

Management

There are now to date some 200 reported cases of gastric schwannoma, with no specific guideline for management of this tumor, with the endoscopists recommending follow the practical guideline in management subepithelial tumors, based on the symptoms of the patient, tumor size and histologic grading (malignancy potential).^{17–20}

1. Symptoms associated with tumor: a tumor with upper GI bleeding, abdominal pain or gastric outlet obstruction needs surgical or endoscopic removal.

2. Asymptomatic with tumor size more than 5 cm: consider surgical removal for definite diagnosis and histologic examination for malignancy potential.

3. Asymptomatic with tumor size 2–5 cm: consider further histologic evaluation by EUS FNA

–GISTs: if the tumor is considered to have malignancy potential, surgical or endoscopic removal should be considered.

–Gastric schwannoma: benign behavior, needs close follow up for 6–12 months, if tumor grows during the follow up period consider surgical or endoscopic removal.

4. Asymptomatic with tumor size less than 2 cm: close follow up with EUS or CT scan for 6–12 months, if tumor grows during the follow up period consider surgical or endoscopic removal.

Surgical resection is the treatment of choice in gastric schwannoma. Symptomatic patients or large tumor size with malignant features are indication for complete resection. The size and location of the tumor, as well as its relation to the surrounding organs, are important factors in determining the operative technique. Wedge resection, partial, subtotal, or total gastrectomy, or laparoscopy are the normal option.²¹ Endoscopic treatment is a less invasive procedure for tumor resection but the procedure needs an experienced endoscopist. A previous study reported successful tumor resection without serious complications, but future studies are needed to compare techniques and outcomes.²²

Prognosis

The gastric schwannoma is a primary benign gastric mesenchymal tumor, rarely malignant, with excellent prognosis after complete removal. Although large tumor size and high mitotic histologic grading (>10 per 50 high–power field (HPF)) are not independent factors for confirmation of malignancy. Contrast with GISTs, the larger tumor size with high mitotic histologic grading (>10 per 50 HPF) also have higher risk to malignancy.^{6,8,23}

Conclusion

The gastric schwannoma is a rare, benign, primary gastric mesenchymal tumor, usually asymptomatic, with about 2–4 times higher incidence in females than males, most commonly occurring during the 5th–6th decades of life. Cross-sectional imaging (CT or MRI) demonstrate a non-specific finding, difficult to differentiate from other subepithelial tumor. An endoscopic ultrasound can be used to identify the origin of the tumor and its intra-tumoral components, however tissue histology and immunohistochemistry are necessary for confirmation.

Management of this tumor depends on the symptoms of the patient, tumor size and mitotic activity as revealed by histology, but most cases have an excellent prognosis without recurrence or meta-stasis after complete surgical or endoscopic removal.

References

- Lin CS, Hsu HS, Tsai CH, Li WY, Huang MH. Gastric schwannoma. *J Chin Med Assoc* 2004;67:583–6.
- McNeer G, Pack GT. *Neoplasms of the stomach*. Philadelphia: J.B. Lippincott; 1974.
- Hou YY, Tan YS, Xu JF, Wang XN, Lu SH, Ji Y, et al. Schwannoma of the gastrointestinal tract: a clinicopathological, immunohistochemical and ultrastructural study of 33 cases. *Histopathology* 2006;48:536–45.
- Daimaru Y, Kido H, Hashimoto H, Enjoji M. Benign schwannoma of the gastrointestinal tract: a clinicopathologic and immunohistochemical study. *Humpathol* 1988;19:257–64.
- Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal tumors (GISTs): a review. *Eur J Cancer* 2002;38:39–51.
- Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1,765 cases with long-term follow-up. *Am J Surg Pathol* 2005;29:52–68.
- Diaz ST, Hansson CM, de Bustos C, Mantripagada KK, Piotrowski A, Benetkiewicz M, et al. High-resolution array-CGH profiling of germline and tumor-specific copy number alterations on chromosome 22 in patients affected with schwannomas. *Hum Genet* 2005;118:35–44.
- Lysandra V, Rebecca M, Jerzy L, Miettinen M. Gastric schwannoma: a clinicopathologic study of 51 cases and critical review of the literature. *Hum Pathol* 2012;43:650–9.
- Evans DG. Neurofibromatosis type 2 (NF2): a clinical and molecular review. *Orphaned J Rare Dis* 2009;4:16.
- Agaimy A, Markl B, Kitz J, Wunsch PH, Arnholdt H, Fuzesi L, et al. Peripheral nerve sheath tumors of the gastrointestinal tract: a multicenter study of 58 patients including NF1-associated gastric schwannoma and unusual morphological variants. *Virchows Arch* 2010;456:411–22.
- Agaimy A, Markl B, Kitz J. Peripheral nerve sheath tumors of the gastrointestinal tract: a multicenter study of 58 patients including NF1-associated gastric schwannoma and unusual morphological variants. *Virchows Arch* 2010;456:411–22.
- Hong HS, Ha HK, Won HJ, Byun JH, Shin YM, Kim AY, et al. Gastric schwannoma: radiological features with endoscopic and pathological correlation. *Clin Radiol* 2008;63:536–42.
- Takeda M, Amano Y, Machida T, Kato S, Naito Z, Kumita S. CT, MRI, and PET findings of gastric schwannoma. *Jpn J Radiol* 2012;30:602–5.
- Yoon W, Paulson K, Mazzara P. Gastric schwannoma: a rare but important differential diagnosis of a gastric submucosal mass. *Case Rep Surg* 2012;2012:280982.
- Hiroki S, Kitano M, Kudo M. Diagnosis of subepithelial tumors in the upper gastrointestinal tract by endoscopic ultrasonography. *World J Radiol* 2010;28:289–97.
- Zhong D, Wang C, Xu J, Chen MY, Cai JT. Endoscopic ultrasound features of gastric schwannomas with radiological correlation: a case series report. *World J Gastroenterol* 2012;18:7397–401.
- Hwang JH, Rulyak SD, Kimmey MB. American gastroenterological association institute technical review on the management of gastric subepithelial masses. *Gastroenterology* 2006;130:2217–28.
- Mekky MA, Yamao K, Sawaki A, Mizuno N, Hara K, Nafeh MA, et al. Diagnosis utility of EUS-guided FNA in patients with gastric submucosal tumors. *Gastrointest Endosc* 2010;71:913–9.
- Sepe PS, Brugge WR. A guide for the diagnosis and management of gastrointestinal stromal cell tumors. *Nat Rev Gastroenterol Hepatol* 2009;6:363–71.
- Kongkam P, Devereaux BM, Ponnudurai P, Rattanachuek T, Sahai AV, Gotoda T, et al. Endoscopic ultrasound forum summary from the Asian Pacific digestive week. *Endosc Ultrasound* 2013;2:43–60.
- Bandoh T, Isoyama T, Toyoshima H. Submucosal tumors of the stomach: a study of 100 operative cases. *Surgery* 1993;113:498–506.
- Cai MY, Xu Jx, Zhou PH, XU MD, Chen SY, Hou J. Endoscopic resection for gastric schwannoma with long-term outcomes. *Surg Endosc* 2016;30:3994–4000.
- Atmatzidis S, Chatzimavroudis G, Dragoumis D, Tsiaousis P, Patsas A, Atmatzidis K. Gastric schwannoma: a case report and literature review. *Hipokratia* 2012;16:280–2.